NASDAQ:GALT - Galectin Therapeutics Stock Price, Forecast & News

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

Galectin Therapeutics Inc. (NASDAQ:GALT) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.03. View Galectin Therapeutics' Earnings History.

Galectin Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Galectin Therapeutics.

1 Wall Street analysts have issued 1 year target prices for Galectin Therapeutics' stock. Their forecasts range from $11.00 to $11.00. On average, they anticipate Galectin Therapeutics' share price to reach $11.00 in the next twelve months. This suggests a possible upside of 270.4% from the stock's current price. View Analyst Price Targets for Galectin Therapeutics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galectin Therapeutics.

News headlines about GALT stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Galectin Therapeutics earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Galectin Therapeutics.

Some companies that are related to Galectin Therapeutics include Akero Therapeutics (AKRO), Omeros (OMER), Cara Therapeutics (CARA), Axovant Sciences (AXON), Vectura Group (VEGPF), Clovis Oncology (CLVS), TherapeuticsMD (TXMD), Kiniksa Pharmaceuticals (KNSA), Kadmon (KDMN), Basilea Pharmaceutica (BPMUF), AC Immune (ACIU), Retrophin (RTRX), BioDelivery Sciences International (BDSI), Phathom Pharmaceuticals (PHAT) and Cytokinetics (CYTK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), Viking Therapeutics (VKTX), Exelixis (EXEL), Intercept Pharmaceuticals (ICPT), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Rigel Pharmaceuticals (RIGL), Verastem (VSTM) and Immunomedics (IMMU).

Galectin Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include D.A. Davidson & CO. (1.44%), State Street Corp (0.98%), California State Teachers Retirement System (0.11%), Wedbush Securities Inc. (0.04%), Squarepoint Ops LLC (0.02%) and Millennium Management LLC (0.02%). Company insiders that own Galectin Therapeutics stock include Fund LP 10X, Gilbert F Amelio, Gilbert S Omenn, Harold H Shlevin, Jack W Callicutt, James C Czirr, Joel Lewis, Kary Eldred, Kevin D Freeman, Marc Rubin, Peter G Traber, Richard E Uihlein and Theodore Daniel Zucconi. View Institutional Ownership Trends for Galectin Therapeutics.

GALT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Wedbush Securities Inc.. Company insiders that have sold Galectin Therapeutics company stock in the last year include Fund LP 10X, Gilbert F Amelio and Marc Rubin. View Insider Buying and Selling for Galectin Therapeutics.

GALT stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, D.A. Davidson & CO., California State Teachers Retirement System and Squarepoint Ops LLC. Company insiders that have bought Galectin Therapeutics stock in the last two years include Jack W Callicutt, Joel Lewis, Kary Eldred, Kevin D Freeman and Richard E Uihlein. View Insider Buying and Selling for Galectin Therapeutics.

Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GALT stock can currently be purchased for approximately $2.97.

Galectin Therapeutics has a market capitalization of $168.95 million. The company earns $-13,900,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Galectin Therapeutics employs 6 workers across the globe.View Additional Information About Galectin Therapeutics.

The official website for Galectin Therapeutics is http://www.galectintherapeutics.com/.

Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected]